Paclitaxel based devices, the current drug used for treating PAD, has raised safety concerns, and Sirolimus based devices have replaced it as a safer, more effective treatment. However, to improve bioavailability, Sirolimus based devices need to be encapsulated and retained in the artery. This has proved to be problematic.
Functionalized nanoparticles (f-NP) are employed to enable and improve uptake and retention of Sirolimus based devices in PAD patients. This allows approximately 12 million people with Peripheral Artery Disease an opportunity for better outcomes.
With the major advancement in drug-coated balloon (DCB) technology, the leadership team sat down and discussed their focus on bringing a better alternative to patients with Peripheral Artery Disease (PAD).
CEO: Marwan Berrada-Sounni, MSc, MBA
A successful entrepreneur with extensive experience in cardiovascular and endovascular devices.
CMO: Mehdi Shishehbor, DO, MPH, PhD
Chief Medical Officer and President, Harrington Heart and Vascular Institute University Hospitals, Cleveland
Vinod Labhasetwar, PhD
Professor and Endowed Chair of Nanomedicine, Department of Biomedical Engineering at Cleveland Clinic Lerner Research
Advanced NanoTherapies is working closely with the FDA to achieve an early feasibility study and introduce its technology to human populations.
to-tissue drug uptake
and multi-drug delivery
No particle release